文献速递脊柱关节炎其他结缔组织病

银屑病或银屑病关节炎患者生物制剂严重感染风险比较

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
PubMed 文献 · Ann Rheum Dis · 2019-10-31

该回顾性队列研究纳入2015至2018年美国商业保险的银屑病或银屑病关节炎成人患者,比较IL-17、IL-12/23和TNF抑制剂起始后严重感染风险。结果显示,在生物制剂初治患者中,IL-12/23抑制剂较TNF和IL-17抑制剂严重感染风险更低;在生物制剂经治患者中,三类药物感染风险无差异。

要点

  • 生物制剂初治的PsO或PsA患者中,IL-12/23抑制剂严重感染风险低于TNF抑制剂(HR=0.59)。
  • IL-17抑制剂与TNF抑制剂或IL-12/23抑制剂相比,严重感染风险无显著差异。
  • 生物制剂经治患者中,TNF、IL-17和IL-12/23抑制剂感染风险无差异。

核心结论

  • 在生物制剂初治的PsO或PsA患者中,IL-12/23抑制剂较TNF和IL-17抑制剂与严重感染风险降低相关。
  • 在生物制剂经治患者中,TNF、IL-17和IL-12/23抑制剂的感染风险无差异。

研究设计与样本

  • 回顾性队列研究,纳入2015至2018年美国商业保险诊断为PsO或PsA的成人患者。
  • 暴露为IL-17(ixekizumab或secukinumab)、IL-12/23(ustekinumab)或TNF抑制剂(adalimumab、certolizumab pegol、etanercept、golimumab和infliximab)的配药。
  • 结局为生物制剂起始后需住院治疗的感染,采用Cox比例风险回归模型并调整逆概率治疗加权倾向评分。

主要发现

  • IL-17与TNF的类别特异性发病率相似,而IL-12/23显著更低。
  • 调整倾向评分后,IL-17与TNF相比严重感染风险无增加(HR=0.89,95%CI 0.48至1.66),与IL-12/23相比亦无增加(HR=1.12,95%CI 0.62至2.03)。
  • IL-12/23与TNF相比严重感染风险更低(HR=0.59,95%CI 0.39至0.90)。

临床怎么用

  • 对于生物制剂初治的PsO或PsA患者,选择IL-12/23抑制剂可能降低严重感染风险。
  • 对于生物制剂经治患者,TNF、IL-17和IL-12/23抑制剂的感染风险相似,选择时需综合考虑其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients. METHODS: We assembled a retrospective cohort of commercially insured adults in the USA diagnosed with PsO or PsA between 2015 and 2018. Exposure was dispensation for IL-17 (ixekizumab or secukinumab), IL-12/23 (ustekinumab) or TNF (adalimumab, certolizumab pegol, etanercept, golimumab and infliximab). The outcome was infection requiring hospitalisation after biologic initiation. Incidence rates (IRs) per 100 person-years were computed, and hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression models, adjusted for inverse probability of treatment-weighted propensity scores. RESULTS: A total of 11 560 new treatment episodes were included. Overall, 190 serious infections (2% of treatment episodes) were identified in 9264 person-years of follow-up. Class-specific IRs were similar among IL-17 and TNF, yet significantly lower for IL-12/23. After adjustment for propensity scores, there was no increased risk with IL-17 compared with either TNF (HR=0.89, 95% CI 0.48 to 1.66) or IL-12/23 (HR=1.12, 95% CI 0.62 to 2.03). By contrast, IL-23/23 were associated with a lower risk of infections than TNF (HR=0.59, 95% CI 0.39 to 0.90). CONCLUSIONS: Relative to TNF and IL-17, IL-12/23 inhibitors were associated with a reduced risk of serious infection in biologic-naïve patients with PsO or PsA. In biologic-experienced individuals, there was no difference in infection risk across TNF, IL-17 or IL-12/23 inhibitors.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Li X, Andersen KM, Chang HY, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2019. PMID: 31672774. doi:10.1136/annrheumdis-2019-216102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。